New drug with immunotherapy for advanced squamous lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug (EVM14) combined with an existing immunotherapy called ivonescimab for people with advanced squamous lung cancer that has not been treated before. The goal is to see if the combination is safe and if it helps shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of lung cancer called squamous non-small cell lung cancer that has spread locally or to other parts of the body (stage III or IV).
- Your tumor must test positive for a protein called PD-L1 (with a score of at least 1%).
- You must not have had any prior cancer treatment for this lung cancer (except if it was for an earlier stage and you've been cancer-free for at least 6 months after that).
- You must have at least one tumor that can be measured on scans.
- You must be able to carry out daily activities (ECOG performance status 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (sintilimab) with chemotherapy and an anti-angiogenesis drug (rh-endostatin) for people with advanced or recurrent squamous non-small cell lung cancer. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests a new combination of three medicines (two chemotherapies and an immunotherapy) for people with a certain type of advanced lung cancer called squamous non-small cell lung cancer. The goal is to see if this combo can help shrink or control the cancer better than current treatments.
This trial tests a new drug called Ivonescimab as the first treatment for people with advanced (stage IV) non-small cell lung cancer whose tumors have high levels of PD-L1 (a protein that helps cancer hide from the immune system). The goal is to see if it can help shrink or control the cancer.
This study tests a new combination of two investigational drugs for people with advanced solid tumors, especially lung cancers. The goal is to see if the combination can shrink tumors or slow their growth.
This trial tests a new drug called ivonescimab combined with a chemotherapy drug (docetaxel) for advanced non-small cell lung cancer. It's for people who have already tried platinum-based chemo and a PD-1/PD-L1 inhibitor, and who have not had docetaxel before.
This trial tests a combination of ivonescimab and docetaxel for people with advanced non-small cell lung cancer who have had a long response (11-15 months without the cancer getting worse) to first-line immunotherapy. The goal is to see if adjusting treatment based on ctDNA-MRD levels can improve outcomes.
Hear when a new Squamous Non-Small Cell Lung Cancer sqNSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.